Prof. PeptideProf. Peptide

Thymosin Alpha-1

Gut Health & ImmunityApproved Internationally

Marketed as: Zadaxin (outside US)

Last reviewed: September 20, 2026

Quick Facts

What it is
A 28-amino-acid immune-modulating peptide from the thymus — it promotes T-cell maturation and is studied for immune support, chronic viral infection, and as a vaccine adjuvant.
How it's taken
Subcutaneous injection, twice weekly to daily depending on protocol
Half-life
~2 hours plasma — immune effects on T-cell maturation persist far longer
Typical research dose
Trial-confirmed: 1.6 mg twice weekly × 6 months (hepatitis B RCT) or 1.6 mg twice daily × 5 days then once daily × 2 days (sepsis RCT). Community-reported (unverified): 250–750 mcg daily — see Dosing section
Research status
Not FDA-approved in the US; approved as Zadaxin in 35+ countries — US research use only.
On this page
  1. 1.Where to source Thymosin Alpha-1
  2. 2.What is Thymosin Alpha-1?
  3. 3.How does Thymosin Alpha-1 work?
  4. 4.What is Thymosin Alpha-1 used for?
  5. 5.How long does Thymosin Alpha-1 take to work?
  6. 6.How is Thymosin Alpha-1 dosed?
  7. 7.How is Thymosin Alpha-1 administered?
  8. 8.What does Thymosin Alpha-1 stack well with?
  9. 9.What are the side effects of Thymosin Alpha-1?
  10. 10.Does Thymosin Alpha-1 interact with other drugs?
  11. 11.How should Thymosin Alpha-1 be stored?
  12. 12.What are the limitations of Thymosin Alpha-1 research?
  13. 13.Thymosin Alpha-1 FAQ
  14. 14.References
  15. 15.Published Studies

Where to source Thymosin Alpha-1

Outside the US, Zadaxin is available by prescription in 35+ countries. In the US, Thymosin Alpha-1 is sold as a research-grade peptide by specialty vendors. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes — including an oral-format option for users who prefer to avoid injection.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 42 vendors

Also stocking Thymosin Alpha-1

BioLongevity Labs, EZ Peptides, Fusion Peptide, GenPeptide — each carries a current price row for this compound.

Compare all 42 vendors stocking Thymosin Alpha-1

See all 88 verified vendors

What is Thymosin Alpha-1?

Thymosin Alpha-1 (also written Tα1 or TA-1) is a 28-amino-acid peptide naturally produced by the thymus gland, where it plays a critical role in T-cell maturation and immune system development. Synthetic Thymosin Alpha-1 (thymalfasin, brand name Zadaxin) is approved as a prescription drug in over 35 countries for treating chronic hepatitis B and hepatitis C, often as an adjunct to interferon therapy. It is also used as an immune-supportive treatment in cancer patients undergoing chemotherapy. While NOT FDA-approved in the United States, Thymosin Alpha-1 has decades of clinical use abroad and one of the strongest evidence bases of any peptide on Prof. Peptide. Distinct from Thymosin Beta-4 (TB-500) despite the shared name. Often paired with BPC-157 or KPV for combined immune + tissue / anti-inflammatory protocols. New to peptide research? Start with the basics

Reported benefits:

  • Enhanced T-cell maturation and function
  • Improved immune response to chronic viral infections (Hepatitis B/C, CMV)
  • Adjunctive support during cancer chemotherapy
  • Modulation of autoimmune conditions (without immunosuppression)
  • Restoration of immune function in immunocompromised states
  • Approved internationally for clinical use (35+ countries)

Common research dose: Subcutaneous injection. The two dosing figures traceable to a cited human RCT are 1.6 mg twice weekly for 6 months (hepatitis B, Mutchnick et al. 1999) and 1.6 mg twice daily for 5 days then once daily for 2 days (severe sepsis, ETASS/Wu et al. 2013). Community-reported (unverified) research-peptide protocols often use 250–750 mcg daily over 4–12 weeks — see the Dosing section for the literature-vs-community comparison.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does Thymosin Alpha-1 work?

Thymosin Alpha-1 promotes T-cell maturation in the thymus and activates innate immunity through Toll-like receptor binding (TLR2, TLR9). It modulates Th1/Th2 balance (favoring cellular anti-viral immunity), enhances natural killer cell cytotoxicity, and does all this WITHOUT generalized immunosuppression — it modulates rather than suppresses, which is what makes it useful in immunocompromised states without infection risk.

  1. T-Cell Maturation [1]. Thymosin Alpha-1 promotes maturation of pre-T cells in the thymus into functional CD4+ and CD8+ T-cells. Critical for adaptive immune response, particularly in immunocompromised states.
  2. Toll-Like Receptor Activation [2]. Activates TLR2 and TLR9 on dendritic cells, enhancing innate immune response and bridging to adaptive immunity. This is part of the mechanism behind antifungal Th1 resistance.
  3. Th1/Th2 Balance Modulation [3]. Promotes Th1 responses (cellular immunity, anti-viral) while modulating Th2 (humoral immunity, allergic). Useful for chronic viral infections where Th1 response is impaired.
  4. Natural Killer Cell Function. Enhances NK cell cytotoxic activity. Important for early viral control and cancer surveillance.
  5. Without Generalized Immunosuppression [4]. Unlike traditional immunosuppressants, Thymosin Alpha-1 modulates rather than suppresses immune function. This balanced effect allows use in autoimmune contexts without infection risk.

What is Thymosin Alpha-1 used for?

Thymosin Alpha-1's research evidence base includes 35+ countries' worth of clinical approval and post-marketing surveillance, though its one identified Phase 3 hepatitis B RCT did not reach statistical significance. Established applications include chronic hepatitis B/C, cancer adjunctive therapy (multiple cancer types), sepsis (a positive Phase III RCT, ETASS), and chronic viral infections. Post-COVID immune dysfunction is a recent growing research interest.

  1. Hepatitis B & C [5][8]. The one Phase III RCT identified for this page (Mutchnick et al. 1999, PMID 10607256, multicenter, randomized, double-blind, placebo-controlled, N=97 chronic hepatitis B patients) found a higher response rate with Thymosin Alpha-1 than placebo (25% vs 13% sustained HBV DNA/HBeAg loss) that did not reach statistical significance (P<0.11); its own conclusion states the results "do not confirm observations of treatment efficacy reported in other clinical studies." An earlier open-label, uncontrolled pilot (Rasi et al. 1996, PMID 9026482, N=15 hepatitis C patients combined with interferon) reported a positive signal but explicitly called for a randomized controlled study to verify it. Zadaxin is approved in many countries specifically for chronic hepatitis B and C on the basis of this and other evidence, not on a confirmed Phase 3 result found for this page.
  2. Cancer Adjunctive Therapy. Used in melanoma, hepatocellular carcinoma, and lung cancer settings to support immune function during chemotherapy. Reduced chemotherapy-related immunosuppression without compromising chemo efficacy.
  3. Sepsis [6]. Multicenter trials in severe sepsis showed reduced 28-day mortality. Mechanism: enhanced T-cell function in immunocompromised septic patients.
  4. Chronic Viral Infections. Cytomegalovirus, herpes zoster, chronic EBV. Benefits in immunocompromised populations. Less formally studied than hepatitis applications.
  5. Post-COVID Immune Dysfunction. Recent research interest in long COVID and persistent post-infection immune dysregulation. Limited but growing evidence base.

How long does Thymosin Alpha-1 take to work?

Thymosin Alpha-1 effects develop progressively. T-cell function changes are measurable in 2–4 weeks. Hepatitis B/C antiviral response is assessed over a 6–12 month protocol. Cancer adjunct effects are protocol-dependent. General immune support typically shows benefit after 4–8 week cycles. The gradual immune modulation profile (rather than acute effect) is consistent with the peptide's role in T-cell development.

T-cell function changes are measurable in 2–4 weeks of consistent dosing. Hepatitis B/C antiviral response is assessed over the 6–12 month protocol that drives approved international use. Cancer adjunct effects are protocol-dependent — most benefit appears during chemotherapy cycles to maintain immune function rather than as direct anti-tumor effect. General immune support typically shows benefit after 4–8 week cycles. The gradual immune-modulation profile (rather than acute effect) is consistent with the peptide's role in T-cell development — restoration of immune cell populations takes weeks rather than hours.

How is Thymosin Alpha-1 dosed?

Two of the cited human RCTs report the exact dose administered — Mutchnick et al. 1999 [8] (hepatitis B) and Wu et al. 2013/ETASS [6] (severe sepsis) — and the two regimens differ from each other and from the cancer-adjunct and general-immune-support figures this page previously listed, neither of which traces to a cited trial. Thymosin Alpha-1 is administered as a subcutaneous injection.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

  1. Chronic hepatitis B, Mutchnick et al. 1999 [8]. Human RCT (Phase III, multicenter, randomized, double-blind, placebo-controlled, N=97). Dose: 1.6 mg subcutaneously twice weekly for 6 months, followed by 6 months of observation. This is the dose the international Zadaxin hepatitis label uses, but the trial's own result at this dose did not reach statistical significance (P<0.11).
  2. Severe sepsis, Wu et al. 2013 (ETASS) [6]. Human RCT (multicenter, single-blind, randomized and controlled, N=361). Dose: 1.6 mg subcutaneously twice daily for 5 days, then once daily for 2 days — a 7-day course, not the 4–8 week course this page previously attributed to a “cancer adjunctive” use. 28-day mortality was lower in the Tα1 group with a marginal significance level (P=0.049 by log-rank).
  3. Cancer adjunctive use: not established by a cited trial. No RCT or trial identified for this page tested Thymosin Alpha-1 as a chemotherapy adjunct at a specific dose; the “1.6 mg daily, 5-on/2-off” figure this page previously listed under that heading actually describes the ETASS sepsis regimen's cadence, not a cancer-specific trial, and has been removed as a cancer-adjunct claim.

Community-reported practice (unverified)

  1. Research peptide (general immune support). 250–750 mcg daily for 4–8 weeks — well below the 1.6 mg doses used in both cited RCTs, and not itself drawn from a trial.
  2. Cancer-adjunct protocols (unverified). Some research-community and off-label clinical sources describe 1.6 mg subcutaneously, daily or every other day, for several weeks during chemotherapy cycles — a real off-label use pattern in some clinics, but not the dose or schedule of any RCT identified for this page.
  3. Reconstitution. Typically 1.6 mg vials supplied as Zadaxin, or 5–10 mg vials for research-grade material.

For research-grade material, reconstitution with bacteriostatic water is standard. The 1.6 mg twice-weekly Mutchnick/Zadaxin hepatitis regimen and the 1.6 mg ETASS sepsis regimen are the two dosing figures on this page traceable to a specific human RCT.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is Thymosin Alpha-1 administered?

Thymosin Alpha-1 is given as a subcutaneous injection — under the skin, not into muscle — using a small insulin syringe. The hepatitis B trial regimen (Mutchnick et al. 1999) was 1.6 mg twice weekly; the sepsis trial regimen (Wu et al. 2013, ETASS) was 1.6 mg twice daily for 5 days then once daily for 2 days. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection. Common sites: abdomen, thigh, upper arm.
  2. Time of day. Any consistent time. Daily consistency matters more than time of day.
  3. With or without food. Either is fine; no fasting requirement.
  4. Site rotation. Reported practice alternates abdomen, thigh, and upper arm to reduce localized irritation.
  5. Missed dose. Reported practice skips and resumes at the next scheduled dose. The convention is not to double-dose.
  6. Reconstitution handling. Bacteriostatic water (or sterile water for clinical Zadaxin use), swirl gently — do not shake.
  7. Cycle structure. Hepatitis: 6 months. Cancer adjunct: 4–8 weeks. General immune: 4–12 weeks.

Timing context. Thymosin Alpha-1's effects on T-cell maturation accumulate over weeks rather than via acute pharmacology. The 1.6 mg twice-weekly schedule was the dose tested in the Mutchnick et al. 1999 [8] hepatitis B RCT and is the basis of the international Zadaxin hepatitis label. The ETASS sepsis RCT (Wu et al. 2013 [6]) used a different, shorter twice-daily-then-once-daily 7-day course. Cancer-adjunct and research-grade lower-dose protocols (250–750 mcg daily) are community-reported and not derived from a cited trial.

AspectReported
FrequencyTrial-confirmed: twice weekly for 6 months (Mutchnick et al. 1999 [8], hepatitis B) or twice daily × 5 days then once daily × 2 days (Wu et al. 2013 [6], sepsis). Community-reported (unverified): daily, for cancer-adjunct or general-immune-support use.
Best time of dayAny consistent time
FoodNo fasting required; inject with or without food
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to Thymosin Alpha-1.
Half-life~2 hours plasma; biological effects on T-cell maturation persist far longer
Steady-stateImmune effects accumulate over weeks; T-cell population changes measurable in 2–4 weeks

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. Zadaxin clinical vials are 1.6 mg; research-grade vials are typically 10 mg. Because dose range spans 250 mcg (research) up to 1.6 mg (Zadaxin), 2 mL reconstitution gives clean unit math. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 10 mg research-grade vial.

BAC waterConcentration250 mcg dose750 mcg dose1.6 mg (Zadaxin)3 mg dose
1 mL10 mg/mL3 units8 units16 units30 units
2 mL5 mg/mL5 units15 units32 units60 units
3 mL3.33 mg/mL8 units23 units48 units90 units

Units vs mcg. At a 10 mg vial, each unit drawn delivers 100 mcg of Thymosin Alpha-1 at 1 mL reconstitution, 50 mcg at 2 mL, and 33 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does Thymosin Alpha-1 stack well with?

Thymosin Alpha-1's most-validated pairing is with interferon for hepatitis B/C — the synergy is evidence-based and clinically approved. It pairs with BPC-157 for combined immune + tissue repair, and with KPV for combined immune modulation + anti-inflammatory effects. The most important non-pairing is active immunosuppressant therapy (cyclosporine, tacrolimus, mycophenolate) — theoretical antagonism since Thymosin Alpha-1 promotes immune function.

  1. Interferon (clinical hepatitis protocols). Synergistic, evidence-based combination — the basis of the Zadaxin hepatitis B/C approved indication.
  2. BPC-157. BPC-157 for combined immune + tissue repair applications.
  3. KPV. KPV for combined immune modulation + anti-inflammatory effects (gut-immune axis protocols).
  4. NAD+. NAD+ sometimes paired in immune optimization protocols (limited evidence).
  5. Conflicts: combination with active immunosuppressant therapy. Theoretical antagonism — Thymosin Alpha-1 promotes immune function while immunosuppressants suppress it.

What are the side effects of Thymosin Alpha-1?

Thymosin Alpha-1 has decades of clinical use under regulated conditions in 35+ countries, with international post-marketing surveillance. The most-reported user effects are mild injection-site reactions and transient mild fever after first few doses. No major adverse events documented in 35+ years of clinical use.

Common (most users)

  1. Mild injection site reactions. Most common, typically mild and self-limiting.
  2. Transient injection site soreness. Resolves within hours.

Less common (moderate)

  1. Mild fatigue. Inconsistent across users.
  2. Mild fever after first few doses. Self-limiting; reflects immune activation.

Serious (rare)

  1. No major adverse events documented in 35+ years of clinical use.
  2. Theoretical antagonism with active immunosuppressant therapy.

Thymosin Alpha-1 has decades of clinical use under regulated conditions in 35+ countries, with international post-marketing surveillance.

Does Thymosin Alpha-1 interact with other drugs?

Thymosin Alpha-1's relevant interactions: synergistic with interferon (evidence-based, basis of approved hepatitis indication), generally compatible with chemotherapy agents (used adjunctively in approved international protocols), theoretical antagonism with immunosuppressants (cyclosporine, tacrolimus, mycophenolate). No major drug-drug interactions documented in clinical use across 35+ years.

  1. Interferon. Synergistic, evidence-based for hepatitis B/C.
  2. Chemotherapy agents. Generally compatible (used adjunctively in approved international protocols).
  3. Immunosuppressants (cyclosporine, tacrolimus, mycophenolate). Theoretical antagonism. Reported practice monitors closely.
  4. Vaccines. Limited data on combination timing; may enhance vaccine response (research interest in elderly populations).
  5. No major drug-drug interactions documented in clinical use.

How should Thymosin Alpha-1 be stored?

  1. Lyophilized: 2–8°C long-term.
  2. Reconstituted: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade Thymosin Alpha-1 remains stable — this page does not state a duration as fact.
  3. The reconstituted solution is not frozen.
  4. Light-sensitive; store in original packaging.
  5. Reconstitution uses bacteriostatic water for injection. Swirl gently — do not shake.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of Thymosin Alpha-1 research?

Thymosin Alpha-1 (thymalfasin) is approved as a prescription drug under the brand name Zadaxin in over 35 countries but is NOT FDA-approved in the United States. The decades of approved international clinical use give Thymosin Alpha-1 one of the strongest evidence bases of any peptide on Prof. Peptide. In the US, research-grade material is sold by specialty peptide vendors. NOT on the WADA prohibited list. Commonly confused with Thymosin Beta-4 (TB-500) — different molecules.

Thymosin Alpha-1 (thymalfasin) is approved as a prescription drug under the brand name Zadaxin in over 35 countries including Italy, China, Mexico, and others — but is NOT FDA-approved in the United States. The decades of approved international clinical use give Thymosin Alpha-1 one of the strongest evidence bases of any peptide on Prof. Peptide.

Research-grade material is sold by specialty peptide vendors in the US. Quality varies; verify Certificate of Analysis.

Anti-doping: Thymosin Alpha-1 is NOT currently on the WADA prohibited list.

The peptide is also distinct from Thymosin Beta-4 (TB-500), which has different mechanisms and applications despite the related name. Patients commonly confuse the two.

Thymosin Alpha-1 FAQ

Is Thymosin Alpha-1 FDA-approved?

Not in the United States. Thymosin Alpha-1 (thymalfasin) IS approved as a prescription drug under the brand name Zadaxin in over 35 countries — including Italy, China, Mexico, and others — primarily for chronic hepatitis B and C. The decades of approved international clinical use give Thymosin Alpha-1 one of the strongest evidence bases of any peptide on Prof. Peptide. In the US, it's sold as a research-grade peptide.

How is Thymosin Alpha-1 different from TB-500 / Thymosin Beta-4?

Different molecules with different mechanisms despite the related name. Thymosin Alpha-1 is a 28-amino-acid peptide that promotes T-cell maturation and activates innate immunity through TLR2/TLR9. Thymosin Beta-4 (TB-500) is a 43-amino-acid actin-binding peptide that drives cellular migration and tissue repair. They share a name but address completely different biological problems — Thymosin Alpha-1 for immune support, TB-500 for tissue repair.

What is Zadaxin?

Zadaxin is the international brand name for synthetic Thymosin Alpha-1 (thymalfasin). It is approved in 35+ countries primarily for chronic hepatitis B and hepatitis C, often as adjunct therapy with interferon. Zadaxin is also used as immune support during cancer chemotherapy. Standard dosing is 1.6 mg subcutaneously twice weekly.

Can Thymosin Alpha-1 help with autoimmune conditions?

Theoretically, yes — through immune modulation rather than immunosuppression. Thymosin Alpha-1 promotes Th1/Th2 balance and can shift autoimmune Th2-dominant patterns. However, this mechanism is double-edged in some autoimmune contexts. How this interacts with active immunosuppressant therapy is not characterized; the relevant authority is the treating their physician — combining with cyclosporine, tacrolimus, or methotrexate has theoretical antagonism (the immunosuppressant suppresses while Thymosin Alpha-1 promotes immune function).

Is it safe to use during chemotherapy?

This is a widely reported international use of Thymosin Alpha-1, though no RCT identified for this page tested a specific cancer-adjunct dosing regimen — the commonly cited 1.6 mg subcutaneous, daily or every-other-day protocol used during chemotherapy cycles is community/clinical-practice-reported rather than trial-derived. Multiple studies in melanoma, hepatocellular carcinoma, and lung cancer settings report reduced chemotherapy-related immunosuppression without compromising chemo efficacy.

Does Thymosin Alpha-1 help with chronic viral infections?

Hepatitis B and C is the most internationally approved use, but the one Phase III RCT identified for this page (Mutchnick et al. 1999, N=97 hepatitis B patients) did not reach statistical significance, and an earlier hepatitis C pilot (Rasi et al. 1996, N=15) was open-label and uncontrolled. Other chronic viral applications (cytomegalovirus, herpes zoster, chronic EBV, post-COVID immune dysfunction) are less formally validated but reported in research and clinical practice.

How long until I see immune benefits?

T-cell function changes are measurable in 2–4 weeks. Hepatitis B/C antiviral response is assessed over a 6–12 month protocol. Cancer adjunct effects are protocol-dependent. General immune support is sometimes reported after a 4–8 week cycle, though no trial or label has been identified establishing this timeframe.

Where can I buy Thymosin Alpha-1?

Outside the US, Zadaxin is available by prescription in 35+ countries. In the US, Thymosin Alpha-1 is sold as a research-grade peptide by specialty vendors. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  2. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-9.
  3. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol. 2003;3(8):1145-50.
  4. King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-78.
  5. Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in chronic hepatitis C. J Viral Hepat. 1996;3(4):191-6.
  6. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicentre, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. https://pubmed.ncbi.nlm.nih.gov/23327199/
  7. Wikipedia. Thymalfasin. https://en.wikipedia.org/wiki/Thymalfasin
  8. Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat. 1999;6(5):397-403. https://pubmed.ncbi.nlm.nih.gov/10607256/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

World Journal of Virology / PMC · 2020Open Access
Thymosin Alpha 1: A Comprehensive Review of the Literature →

Dominari A, Hathaway III D, et al.

The most comprehensive English-language review of Thymosin Alpha-1, covering its biology, mechanisms, and clinical applications across multiple disease states. The review documents FDA orphan drug approval for thymalfasin for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma.

Molecules (MDPI) · 2023Open Access
Thymosin Alpha-1 and Its Role in Viral Infectious Diseases — Mechanism and Clinical Application →

Tao N, Xu X, Ying Y, et al.

A mechanistic deep-dive into how Thymosin Alpha-1 enhances immune responses against viral infections. The paper documents Tα1's interaction with Toll-like receptors (TLR3, TLR4, TLR7, TLR9) — activating downstream IRF3 and NF-κB pathways, promoting proliferation and activation of T cells, B cells, macrophages, and natural killer cells.

International Immunopharmacology / ScienceDirect · 2023Paywalled
Thymosin Alpha-1 in Cancer Therapy — Immunoregulation and Potential Applications →

Wei Y, Zhang Y, Li P, et al.

A 2023 review documenting Tα1's emerging role in cancer immunotherapy — particularly its potential synergy with immune checkpoint inhibitors (ICIs). Preclinical evidence that Tα1 can convert 'cold tumors' into 'hot tumors' by reversing macrophage polarization, which could meaningfully enhance the efficacy of checkpoint inhibitors.

International Immunopharmacology / PubMed · 2023Open Access
Thymosin Alpha-1 — Reimagine Its Broader Applications in the Immuno-Oncology Era →

Mao L

A clinical review documenting Tα1's emerging role in modern oncology. The paper documents that Tα1 significantly improved overall survival in surgically resectable non-small cell lung cancer and liver cancer patients. For locally advanced unresectable NSCLC, it significantly reduced chemoradiation-induced lymphopenia and pneumonia.

International Journal of Molecular Sciences (MDPI) · 2025Open Access
Aging and Thymosin Alpha-1 — Immunosenescence and Therapeutic Potential →

Simonova MA, Ivanov I, et al.

A 2025 review examining Tα1's potential role in combating age-related immune decline (immunosenescence). Clinical studies show Tα1 can improve vaccine responses in elderly populations and mitigate immunosenescence markers. The review also covers a promising fusion protein (Refnot) combining Tα1 with TNFα that shows enhanced antitumor activity with reduced toxicity.

Gut Health & ImmunityImmune ModulatorApproved InternationallyResearch-Grade

Related Peptides

KPVBPC-157TB-500GHK-CuNAD+

We may earn commissions from peptide vendor affiliate links.

Have a question about Thymosin Alpha-1? Send us an email